Montana is taking significant steps to position itself as a hub for experimental medical treatments, following the introduction of new legislation aimed at facilitating access to innovative drugs. As of this week, biotech companies in Montana can apply for approval from a newly established review board to market their drugs, even if these treatments have only undergone preliminary testing, often involving small groups of healthy individuals. Once approved, these companies can distribute their products through specialized experimental treatment clinics, with the first of these facilities expected to commence operations by the end of the year.
This right-to-try legislation is notable for its broad access provisions. Individuals who provide informed consent and can afford the associated costs are eligible to access these experimental drugs. This approach has garnered support, particularly among those in the longevity community who view it as a beacon of hope. However, concerns about ethical implications and potential risks have also been raised, sparking a debate on the safety and morality of such experimental access.
Among those advocating for this expanded access is Kris DeVault, a parent whose son, Brody, suffers from creatine transporter deficiency, a rare condition affecting energy supply to the brain and muscles. With no established cures available, DeVault is eager to explore a promising drug currently in early development stages. Although it has only been tested in animals and a limited number of healthy adults, the new legislation may offer him a pathway to potentially life-changing treatment. This situation highlights the personal stakes involved in Montana’s experimental drug initiatives and raises questions about the balance between innovation and patient safety.
Source: The Download: Montana’s new experimental drug rules via MIT Technology Review